<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091896</url>
  </required_header>
  <id_info>
    <org_study_id>IBEViH</org_study_id>
    <secondary_id>IBEViH</secondary_id>
    <nct_id>NCT01091896</nct_id>
  </id_info>
  <brief_title>Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage</brief_title>
  <official_title>Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage Secondary to Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of pre and intra-operative bevacizumab
      injection on postoperative vitreous hemorrhage after diabetic vitrectomy in comparison to
      vitrectomy without bevacizumab injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative vitreous hemorrhage is a common complication after vitrectomy for proliferative
      diabetic retinopathy. Bevacizumab (Avastin) is a potent inhibitor of angiogenesis and has
      been shown to decrease retinal and iris neovascularization in proliferative diabetic
      retinopathy. We believe that preoperative bevacizumab injection could reduce postoperative
      vitreous hemorrhage by decreasing the amount of abnormal vessels and intraoperative injection
      could also reduce postoperative vitreous hemorrhage by inhibiting the vessel formation after
      surgery
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent vitreous hemorrhage incidence after vitrectomy</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual outcome</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Vitreous Hemorrhage Secondary to PDR</condition>
  <arm_group>
    <arm_group_label>1 - no bevacizumab</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive bevacizumab before nor during vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2- bevacizumab before vitrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3- bevacizumab after vitrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy</description>
    <arm_group_label>2- bevacizumab before vitrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy</description>
    <arm_group_label>3- bevacizumab after vitrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing first vitrectomy for vitreous hemorrhage secondary to
             proliferative diabetic retinopathy

        Exclusion Criteria:

          -  follow-up period of less than 3 months

          -  not first vitrectomy

          -  abnormal blood coagulation

          -  uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Almeida, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hospital das Clínicas de Ribeirão Preto - USP</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital das Clínicas de Ribeirão Preto - University of São Paulo</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>SP</state>
        <zip>14049-990</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Almeida, MD</last_name>
      <phone>16 3602-2523</phone>
      <phone_ext>2523</phone_ext>
      <email>felipeppalmeida@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Felipe Almeida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol. 2008 Jun;86(4):385-9. Epub 2007 Nov 7.</citation>
    <PMID>17995982</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <last_update_submitted>March 23, 2010</last_update_submitted>
  <last_update_submitted_qc>March 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hospital das Clínicas de Ribeirão Preto - University of São Paulo</name_title>
    <organization>USP</organization>
  </responsible_party>
  <keyword>bevacizumab</keyword>
  <keyword>vitreous hemorrhage</keyword>
  <keyword>diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Vitreous Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

